About this item:

279 Views | 182 Downloads

Author Notes:

Correspondence and reprint requests: Dr. Veronika Bachanova, Blood and Marrow Transplant Program, University of Minnesota, Mayo Mail Code 480; 420 Delaware Street SE, Minneapolis, MN 55455.

The authors thank the following authors for their contributions to the manuscript: Mahmoud D. Aljurf, Christopher Dandoy, John Gibson, Mark S. Hertzberg, Richard F. Olsson, Bipin N. Savani, Harry C. Schouten, Leo F. Verdonck and Ravi Vij. The authors also thank Maggie Simaytis for administrative support.

There are no conflicts of interest to report.


Research Funding:

The CIBMTR is supported by Public Health Service grant/cooperative agreement [U24-CA076518] from the National Cancer Institute, the National Heart, Lung, and Blood Institute and the National Institute of Allergy and Infectious Diseases; a grant/cooperative agreement [5U10HL069294] from National Heart, Lung, and Blood Institute and National Cancer Institute; a contract [HHSH250201200016C] with Health Resources and Services Administration; 2 grants [N00014-12-1-0142] and[N00014-13-1-0039] from the Office of Naval Research.

The CIBMTR is also supported by grants from several entities, listed in the Acknowledgments of the full article.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology
  • Immunology
  • Transplantation
  • Non-Hodgkin lymphoma
  • Allogeneic transplantation
  • Positron emission tomography
  • SCAN

Impact of Pretransplantation F-18-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma

Show all authors Show less authors


Journal Title:

Biology of Blood and Marrow Transplantation


Volume 21, Number 9


, Pages 1605-1611

Type of Work:

Article | Post-print: After Peer Review


Assessment with 18F-fluorodeoxy glucose (FDG)—positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non—Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with worse OS (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), PFS (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.

Copyright information:

© 2015 American Society for Blood and Marrow Transplantation.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote